Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Management of Bleeding in Patients Taking Oral Anticoagulants
JAMA 319:2032-2033, Anderson, I.,et al, 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy
JAMA 320:1485-1486, Sholzberg, M. & Xu, Y., 2018
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017
Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016
Risk of Gastrointestinal Bleeding Associated with Oral Anticoagulants: Population Based Retrospective Cohort Study
BMJ 350:h1585, h1679, Chang, H.Y.,et al, 2015
Comparative Risk of Gastrointestinal Bleeding with Dabigatran, Rivaroxaban, and Warfarin: Population Based Cohort Study
BMJ 350:h1857, h1979, Abraham, N.S.,et al, 2015
Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015
FDA Approves Praxbind, the First Reversal Agent for the Anticoagulant Pradaxa
JAMA 314:2227, , 2015
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014
Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated with Dabigatran or Warfarin
Stroke 45:2286-2291, Alonso, A.,et al, 2014
Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012
Intracraial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation with Warfarin or Dabigatran
Stroke 43:1511-1517, Hart, R.G.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Acutely Injured Patients on Dabigatran
NEJM 365:2039-2040, Cotton, B.A.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009